CytoSorbents Corp (CTSO) - שווי שוק לרווח

Cytosorbents (CTSO) leads the development of blood filtration systems for severe pathologies, supplying solutions to intensive care units. The company's technological base is integrated into hospital equipment to combat systemic inflammation. Despite a narrow specialization in a single field, the business is scaling globally. This price chart on the GURU.Markets platform shows that this multiple is -1.00.

The P/E ratio measures the market value of a single unit of net profit, allowing an investor to determine the extent of overpayment for an asset or the risk of business undervaluation in real time. The current price-to-earnings ratio of -1.00 reflects market expectations regarding the monetization of Cytosorbents unique patents in the extracorporeal blood purification niche and the steady demand for proprietary consumables.